REC-7735 / Recursion Pharmaceuticals - LARVOL DELTA

REC-7735 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=90 | Recruiting | Sponsor: Recursion Pharmaceuticals Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • PIK3CA

REC-7735 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=90 | Not yet recruiting | Sponsor: Recursion Pharmaceuticals Inc.

New P1/2 trial • Oncology • Solid Tumor • PIK3CA

REC-7735: A potent, mutant-selective PI3Kα H1047R inhibitor with preclinical efficacy across multiple solid tumors and no hyperglycemia or other metabolic liabilities (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Oncology • Solid Tumor • PIK3CA

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "Upcoming milestones: REC-617 (CDK7): On track to initiate CDK7 combination studies in 1H25, additional monotherapy data expected in 2H25; REC-7735 (PI3Kα H1047R): Preclinical studies ongoing with development candidate expected in 2H25; REC-1245 (RBM39): Early Phase 1 safety and PK monotherapy data expected in 1H26."

P1 data • P1/2 data • Pipeline update • Solid Tumor